Enveric Biosciences (Enveric Biosciences) Forward Dividend Yield % : 0.00% (As of May. 31, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Forward Dividend Yield %?

As of today (2024-05-31), the Forward Annual Dividend Yield of Enveric Biosciences is 0.00%.

As of today (2024-05-31), the Trailing Annual Dividend Yield of Enveric Biosciences is 0.00%.

ENVB's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful Forward Dividend Yield % only.

Enveric Biosciences's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Enveric Biosciences's Forward Dividend Yield %

For the Biotechnology subindustry, Enveric Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Forward Dividend Yield % falls into.

Enveric Biosciences Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Enveric Biosciences (NAS:ENVB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Enveric Biosciences Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences (Enveric Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

SLZA:Germany

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Executives

Frank Pasqualone	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney	officer: Chief Financial Officer	10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey	officer: Chief Financial Officer	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil	director	C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson	director	1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel	officer: Chief Technical Officer	3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker	director, officer: Chief Executive Officer	3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini	officer: Chief Scientific Officer	155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward	officer: Chief Financial Officer	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind	director
Marcus Schabacker	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer	director	150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson	director, officer: CEO and Chairman	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins	officer: Chief Medical Officer	C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103